Michael Zhong

[IJMSC @IJMSCtweets]

Correlation between reduced telomere length & disability severity in #MultipleSclerosis, suggesting link between biological aging, neurological reserve & immune dysfunction. https://t.co/WaIdUMuJVQ
@mzhong23 @vjokubaitis @STMneurosci

[Francesca Bridge @fm_bridge]

Excited to share my latest review article on the impact of #menopause on #MultipleSclerosis in Autoimmunity Reviews! 🌟It explores the relationship between menopause and MS, shedding light on how hormonal changes can influence MS trajectory 🧠 👉 https://t.co/fwnpwQtEpE

[Michael Zhong @mzhong23]

@anneke_vdw @CCSNeurosci @vjokubaitis @HelmutButz Thank you! Could not have done it without you all. It's been such a great experience and environment to do it.

[AnnekeVdWalt @anneke_vdw]

WE ARE RECRUITING! A dream job for a neurology trainee who wants to be a subspecialist Neuroimmunologist. This is a full-time position with research and clinical requirements, starting in Feb 2023. https://t.co/PIRmpS80Wf

[Translational Medicine at Monash University @MonashSTM]

Participants sought: Immunobiology of pregnancy in #MS and #NMOSD @vjokubaitis @MonashNeurosci @MonashImmPath @MS_Australia @IntNatlWiMS @MSNA_Inc @ozwims https://t.co/QwFUaPccSr

[Assoc Professor Vilija Jokubaitis @vjokubaitis]

Our guidelines for pregnancy and breastfeeding for women with #MultipleSclerosis can now be found on the @MSBrainHealth site https://t.co/GbUn686yFI

Take home messages for women with #MS is that they should: 🧵 1/5

[Michael Zhong @mzhong23]

@MSJ_Research @MSBase_Registry Evidence to guide DMT switches is needed. Here, the hazard of 6m-CDP on ocrelizumab was predicted by longer washouts (>2m) from the prior DMT. Switch from fingolimod was independently associated with a greater short-term relapse hazard (first 3m on ocrelizumab).

[Michael Zhong @mzhong23]

Very happy to share our new paper in @MSJ_Research: we looked at relapses and disability progression in 1096 patients from the @MSBase_Registry after they switched to ocrelizumab from a prior DMT.

https://t.co/dkDhwW3t6Z

[Michael Zhong @mzhong23]

@vjokubaitis Dear Melbournians, I am basically from the huddle you do not have a great day is it possible to get a chance to look at the Bar might be a good time to go the next few days and I will be in the lab when I didn't understand that you are not the intended recipient

[Michael Zhong @mzhong23]

@NehaDietitian @SandroDemaio Thanks Neha!

[AnnekeVdWalt @anneke_vdw]

Anyone want to join a vibrant and innovative team?? We are advertising for a MSNI @AlfredHealth Senior research nurse coordinator and a Ethics and admin officer! PM me for details! @LouiseRath2 @MSResearchAust @MSNA_Inc

[Michael Zhong @mzhong23]

@skyekinder I guess one of the rebuttals from the anti-vax and anti-mask perspective would be that schools and childcares (even private) do it (no jab no play), and businesses did it for masks.

[AnnekeVdWalt @anneke_vdw]

Very proud to share our paper published in @MJA today on Vaccinations in patients with multiple sclerosis: review and recommendations. Pre-COVID but similar principles apply! @LouiseRath2 @mzhong23 @peripatetical @HelmutButz @MasturaMonif @wz_yeh https://t.co/BZPwPBZHtz

[Associate Professor Mastura Monif @MasturaMonif]

Risk of infection in MS patients on Ocrelizumab is not uniform. Increasing IgA and IgG were associated with reduced odds of infection. Hot off the press - read Nabil Seery's paper below. Well done Nabil!
#MS
#DMTs
#Ocrelizumab
#infections

https://t.co/sYdObvdC9X

[Francesco Crescenzo @fr_crescenzo]

A novel prognostic score to assess the risk of progression in relapsing‐remitting multiple sclerosis patients

Our work just published

Never forget gray matter damage in #MultipleSclerosis!!!

Well done @pisani_annalisa @AnToSc

https://t.co/tBRtr1714G

[Michael Zhong @mzhong23]

@mindbodymiko Cheers Jana so now I'm definitely reading it

[Michael Zhong @mzhong23]

@mannersj They really took their motto seriously!

[Michael Zhong @mzhong23]

@MasudHusain @Brain1878 @ajlees This was just great, both the nostalgia and the analogy.. looking forward to more of this series

[Michael Zhong @mzhong23]

Many thanks for your help with this, and well, everything @vjokubaitis @anneke_vdw @JimStankovich @HelmutButz @PiaCampagna. Just the start of more at @MonashNeurosci @CCSMonash @AlfredHealth.

[Michael Zhong @mzhong23]

Very pleased to share this review of rituximab pharmacogenetics. Variants that affect rheumatology and haematology outcomes may well be relevant to MS monoclonal agents. Just published in Neurotherapeutics, it's viewable here: https://t.co/yv0Ahio2UC.

https://t.co/3n9S00faTB